Aave just asked its DAO for $50 million to build the future of DeFi lending. Aave is asking for capital to build products. Pepeto already has three products announcedAave just asked its DAO for $50 million to build the future of DeFi lending. Aave is asking for capital to build products. Pepeto already has three products announced

Best Crypto Presale to Invest in 2026: Aave Bets $50M on Revenue as Pepeto Targets 537x and Bitcoin Hyper Builds Layer 2 Rails

2026/03/07 11:54
5 min read
For feedback or concerns regarding this content, please contact us at [email protected]

Aave just asked its DAO for $50 million to build the future of DeFi lending. Aave is asking for capital to build products. Pepeto already has three products announced by the team and approaching launch while the presale is still open. That difference is why one is a mature governance play and the other is the best crypto presale to invest in 2026.

Aave Labs proposes $50M funding package with 100 percent DAO revenue redirect

Aave Labs submitted a governance proposal requesting up to $42.5 million in stablecoins, $25 million upfront and $17.5 million tied to product milestones, along with 75,000 AAVE tokens. In exchange, the labs would redirect all revenue from user facing products including the Aave App, Aave Card, and Aave Pro back to the DAO treasury. The proposal also seeks to ratify Aave V4 as the long term technical foundation. According to CoinDesk, AAVE is currently trading around $116, having fallen more than 50 percent from its all time high of $661. For DAO participants, the framework validates that revenue is the benchmark metric for sustainable protocol value.

Best Crypto Presale to Invest in 2026: Aave Bets $50M on Revenue as Pepeto Targets 537x and Bitcoin Hyper Builds Layer 2 Rails

Bitcoin Hyper HYPER: Building Layer 2 infrastructure with $31.5M raised and triple audits

Bitcoin Hyper has raised over $31.5 million positioning the first Bitcoin Layer 2 solution powered by the Solana Virtual Machine. HYPER uses zero knowledge rollups to bundle transactions off chain and submit single proofs to Bitcoin’s mainnet, targeting sub cent gas fees. According to CoinMarketCap, the project carries audits from SolidProof, Coinsult, and SpyWolf, with mainnet launching before exchange listings. Analysts target 10x to 20x gains by late 2026 as Bitcoin DeFi and gaming adoption scales. Solid infrastructure thesis with capital intensive development and established L2 competition as the main constraints.

Bitcoin price prediction 2026: BTC holds $68K with target range of $90K to $130K

Bitcoin is trading at $68,000 with institutional analysts forecasting a recovery to $90,000 to $130,000 by mid-2026 as the CLARITY Act advances and ETF demand rebuilds. The halving scarcity effect takes 6 to 9 months to fully work through supply, with the strongest price impact expected in Q3 and Q4 2026. Long term holders are accumulating at current levels with conviction that the cycle bottom is in.

Best crypto presale to invest in 2026: The DOGE to SHIB to PEPE to Pepeto story

Bitcoin’s days of 300x returns for new buyers are behind it. Aave is asking for $50 million to build what retail investors already need. Bitcoin Hyper is building excellent infrastructure. None of that is where the life changing returns in this cycle come from for a new buyer in 2026.

They come from knowing the pattern. DOGE launched at a fraction of a cent and became a household name. SHIB launched as a joke and built a community that made millionaires. PEPE launched with no product and hit a $7 billion market cap. The founders who built PEPE came back. They built PepetoSwap, a cross chain bridge, and a full trading exchange.

All three announced by the team, all approaching launch. Dual audits from SolidProof and Coinsult with zero vulnerabilities. $7.391 million raised. The token is at $0.000000186 with a 537x return target at $0.0001.

An $11,000 entry at current presale prices targets $5,907,000 at the 537x listing price. Aave is building for the future of DeFi. Bitcoin Hyper is scaling Bitcoin. Pepeto is following the exact playbook that already produced a $7 billion asset, this time with products. You missed DOGE. You missed SHIB. You missed PEPE at launch. The presale for the next chapter is open right now.

Why Pepeto is the best crypto presale to invest in over AAVE and Bitcoin Hyper

AAVE at $116 is a governance and revenue sharing play with upside capped by mature DeFi market conditions. Bitcoin Hyper targets 20x with solid infrastructure. Pepeto at $0.000000186 with a 537x return target, PEPE founders, three DeFi products approaching launch, and $7.391 million raised is the only presale in 2026 where the return math still looks like the early DOGE or PEPE entry window. This is that window.

Click To Visit Pepeto Website To Enter The Presale

FAQs

What is the best crypto presale to invest in 2026?

The best crypto presale to invest in 2026 is Pepeto. Created by the PEPE founders, priced at $0.000000186 with a 537x return target at $0.0001, $7.391 million raised, dual zero vulnerability audits from SolidProof and Coinsult, and three DeFi products announced and approaching launch.

Is Aave AAVE a good investment at $116?

Aave at $116 is a solid DeFi governance play with a strong $27 billion TVL and a $50 million revenue redirect proposal that supports long term protocol value. For investors seeking stronger near term return potential, Pepeto at $0.000000186 with a 537x listing target is the better asymmetric opportunity.

How does Bitcoin Hyper compare to Pepeto as a presale investment?

Bitcoin Hyper targets 10x to 20x with strong Layer 2 infrastructure and triple audits. Pepeto offers a 537x return target at listing with PEPE founders, three DeFi products approaching launch, and $7.391 million raised. For maximum asymmetric upside, Pepeto’s 537x from a $0.000000186 presale entry is the stronger opportunity in 2026.

Comments
Market Opportunity
AaveToken Logo
AaveToken Price(AAVE)
$110.48
$110.48$110.48
-0.35%
USD
AaveToken (AAVE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09